{"preliminary_commentary":{"by_channel":{"youtube":11,"podcast":4,"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02292758\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"BOND-3","nct_id":"NCT02292758","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bond-3-nct02292758. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (cetuximab, bevacizumab, irinotecan)","type":"EXPERIMENTAL"},{"description":"Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (cetuximab, placebo, irinotecan)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2019-09-27","type":"ACTUAL"},"conditions":["Colorectal Adenocarcinoma","RAS Wild Type","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"enrollment":{"count":36,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bevacizumab","otherNames":["Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF rhuMAb","Avastin","Bevacizumab awwb","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","BP102","BP102 Biosimilar","HD204","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501"],"type":"BIOLOGICAL"},{"name":"Cetuximab","otherNames":["Cetuximab Biosimilar CDP-1","Cetuximab Biosimilar CMAB009","Cetuximab Biosimilar KL 140","Chimeric Anti-EGFR Monoclonal Antibody","Chimeric MoAb C225","Chimeric Monoclonal Antibody C225","Erbitux","IMC-C225"],"type":"BIOLOGICAL"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Placebo","otherNames":["placebo therapy","PLCB","sham therapy"],"type":"OTHER"}],"last_update":"2022-01-31","lead_sponsor":"Academic and Community Cancer Research United","official_title":"BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-03-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months"},{"measure":"6-month and 12-month Progression-free Survival (PFS) Rates","timeFrame":"From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months"}],"references":[{"citation":"Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 Apr 5;27(4):292-298. doi: 10.1093/oncolo/oyab025.","pmid":"35380713","type":"DERIVED"}],"start_date":{"date":"2014-12-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","url":"https://clinicaltrials.gov/study/NCT02292758"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bond-3-nct02292758"}